FDA clear Ethicon's vessel harvest device:
This article was originally published in Clinica
Executive Summary
Johnson & Johnson company Ethicon has gained US FDA 510(k) clearance for its Clearglide precision bipolar device, which is to be used with the company's minimally invasive system for harvesting saphenous veins used in heart bypass surgery. The product is a sterile, single-patient-use instrument that clamps, coagulates and transects tissue with an integral knife blade. It also uses a patented offset electrode technology, which the company claims can reduce injury to the vessel and surrounding tissue. The device will be offered through Ethicon's Cardiovations division and will complement the company's Clearglide Accel endoscopic harvest system.
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.